Founded in 2008, CYNBIOSE is specialized in preclinical research services with a core expertise and focus on the non-human primate (NHP) model.
Cynbiose supports the risk reduction of candidate drugs and therapeutics of the human microbiome with various hybrid services and exploratory designs to bridge the gap between preclinical and clinical development.
They provide personalized and value-added services in a high-quality environment and work closely with our customers to build a long-term relationship.
CYNBIOSE is also investing in R&D programs to develop innovative NHP models for the study of microbiota and infectious diseases.
Cynbiose launched CYNBIOME ® late 2019, the first excellence network on microbiota and infectious diseases based on the Non-Human Primate (NHP) model.
This network will take full advantage of the synergy between local stakeholders by creating a division for the preclinical investigation of the microbiome.
The aim of the network is to develop this model and the relevant analytical tools through collaborative R&D projects. This will allow CYNBIOME® to offer unique preclinical services in the field of microbiome and infectious diseases, centered on the use of the NHP model.